Norditropin Nordiflex (Somatropin)

Somatropin mimics natural growth hormone by binding to growth‑hormone receptors, activating intracellular JAK2‑STAT5 signaling. This triggers the liver to produce insulin‑like growth factor‑1 (IGF‑1), which promotes bone growth, protein synthesis, and metabolic effects that support linear growth and body composition.

The dose of Norditropin Nordiflex is individualized. A qualified prescriber determines the amount, frequency, and duration based on the patient’s age, weight, IGF‑1 levels, and clinical response, following established pediatric or adult growth‑hormone guidelines.

Safety data for somatropin during pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Norditropin Nordiflex is a recombinant somatropin delivered via a prefilled pen, offering convenient dosing and precise dose adjustment. Compared with other brands such as Genotropin or Saizen, it provides similar efficacy and safety profiles, with the main differences lying in device design, formulation stability and manufacturer support.

The product must be stored refrigerated between 2 °C and 8 °C. Keep it in the original packaging, protect it from light, and do not freeze or shake the pen. If a short period at room temperature is unavoidable, limit exposure to less than 30 minutes.

Norditropin Nordiflex is given as a subcutaneous injection using the prefilled pen. The injection site is typically the thigh, abdomen or upper arm. Patients or caregivers are trained to select an appropriate site, clean the skin, and administer the dose as prescribed.

Serious risks include intracranial hypertension, slipped epiphysis (growth‑plate separation), hyperglycemia or new‑onset diabetes, and possible tumor recurrence in patients with a history of malignancy. Prompt medical evaluation is required if symptoms such as severe headache, visual changes, joint pain or abnormal glucose levels occur.

Norditropin Nordiflex is contraindicated in individuals with active malignancy, known hypersensitivity to somatropin or any excipients, and in patients with uncontrolled diabetes or severe insulin resistance without proper monitoring. It should also be avoided in those with acute critical illness unless specifically indicated.